Table 2 Main characteristics of the participants

From: Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis

  Dodick et al. [12 Vladimir Skljarevsk (2018) Detke et al. [16] Stauffer et al. [14] Skljarevski et al. [13]
Galcanezumab 150 mg Placebo Galcanezumab Placebo Galcanezumab 120 mg Galcanezumab 240 mg Placebo Galcanezumab 120 mg Galcanezumab 240 mg Placebo Galcanezumab 120 mg Galcanezumab 240 mg Placebo
  n = 107 n = 110 n = 273 n = 137 n = 278 n = 277 n = 558 n = 213 n = 212 n = 433 n = 231 n = 223 n = 461
Age (years) 40·9 (11·4) 41·9 (11·7) 40.6 (11.9) 39.5 (12.1) 39.7 (11.9) 41.1 (12.4) 41.6 (12.1) 40.9 (11.9) 39.1 (11.5) 41.3 (11.4) 40.9 (11.2) 41.9 (10.8) 42.3 (11.3)
Women in participants 88 (82%) 96 (87%) 231 (84.6%) 109 (79.6%) 237 (85%) 226 (82%) 483 (87%) 181 (85%) 175 (82.6%) 362 (83.6%) 197(85.3%) 191(85.7%) 393(85.3%)
White in participants 76 (71%) 74 (67%)    223 (80%) 224 (81%) 432 (77%) 169 (79.3%) 165 (77.8%) 356 (82.2%) 166(71.9%) 152(68.2%) 325(70.5%)
Body-mass index (kg/m2) 29·44 (6·3) 29·03 (7·5)    26.4 (5.5) 26.7 (5.2) 26.9 (5.6) 27.8 (5.3) 28.6 (5.7) 28.6 (5.5)    
Migraine illness duration (years)      20.4 (12.7) 20.1 (12.7) 21.9 (12.9) 21.1 (13.0) 19.3 (11.9) 19.9 (12.3) 19.93 (11.7) 20.01 (12.1) 21.2 (12.8)
MHD (mo) 6·7 (2·4) 7·0 (2·5) 6.7 (2.6) 6.6 (2.7) 19.4 (4.3) 19.2 (4.6) 19.6 (4.6) 9.2 (3.1) 9.1 (2.9) 9.1 (3.0) 9.07 (2.9) 9.06 (2.9) 9.2 (3.0)
MHD with acute medication use (mo)      15.1 (6.3) 14.5 (6.3) 15.5 (6.6) 7.4 (3.7) 7.3 (3.3) 7.4 (3.5) 7.47 (3.3) 7.47 (3.3) 7.6 (3.4)
MHD category ≥ 8         140 (65.7%) 139 (65.6%) 285 (65.8%) 154 (66.7%) 151 (67.7%) 307 (66.6%)
Migraine attacks (mo) 4·9 (1·6) 5·0 (1·7) 4.7 (1.6) 4.7 (1.5)     5.6 (1.7) 5.7 (1.8) 5.8 (1.7) 5.54 (1.8) 5.66 (1.8) 5. 7 (1.8)
History of aura 46 (43%) 44 (40%)    153 (55%) 141 (51%) 310 (56%)       
Headache (d/mo)      21.2 (4.0) 21.4 (4.1) 21.5 (4.1)     10.56 (3.4) 10.74 (3.7) 10.7 (3.5)
Headache (h/mo)      144.7 (85.4) 145.9 (93.4) 145.1 (95.1) 59.9 (40.0) 65.0 (60.2) 58.8 (39.4)    
Prior preventive treatment      211 (76%) 220 (79%) 435 (78%)a 133 (62.4) 125 (59.0) 257 (59.4) 157 (68.0%) 144 (64.6%) 298 (64.6%)
Acute headache medication overuse      178 (64%) 177 (64%) 353 (63%) 67 (31.5%) 62 (29.3%) 146 (33.7%)    
MSQ RF-R score      39.3 (17.3) 38.9 (17.3) 38.4 (17.2) 51.4 (16.2) 48.8 (16.8) 52.9 (15.4) 52.5 (14.8) 51.7 (16.3) 51.4 (15.7)
PGI-S score      4.8 (1.2) 4.9 (1.3) 4.9 (1.2) 4.4 (1.1) 4.5 (1.1) 4.2 (1.1) 4.1 (1.2) 4.2 (1.2) 4.3 (1.2)